On June 2, 2025, Telomir Pharmaceuticals announced its participation in the BIO International Convention in Boston from June 16-19, and provided updates on its lead candidate, Telomir-1, aiming for an IND submission by year-end and first-in-human trials in 2026, with significant preclinical progress reported, including a ~50% tumor growth reduction in prostate cancer models.